clofazimine has been researched along with Adverse Drug Event in 11 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead to death." | 2.66 | Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. ( Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020) |
| "Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated." | 1.72 | Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. ( Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022) |
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "Clofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resistant strains in vitro and in animal studies." | 1.38 | Clofazimine in the treatment of multidrug-resistant tuberculosis. ( Jiang, RH; Xiao, HP; Xu, HB, 2012) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Watanabe, F | 1 |
| Furuuchi, K | 1 |
| Hanada, K | 1 |
| Fujiwara, K | 1 |
| Uesugi, F | 1 |
| Hiramatsu, M | 1 |
| Yoshiyama, T | 1 |
| Shiraishi, Y | 1 |
| Kurashima, A | 1 |
| Ohta, K | 1 |
| Morimoto, K | 1 |
| Lan, Z | 1 |
| Ahmad, N | 1 |
| Baghaei, P | 1 |
| Barkane, L | 1 |
| Benedetti, A | 1 |
| Brode, SK | 1 |
| Brust, JCM | 1 |
| Campbell, JR | 1 |
| Chang, VWL | 1 |
| Falzon, D | 1 |
| Guglielmetti, L | 1 |
| Isaakidis, P | 1 |
| Kempker, RR | 1 |
| Kipiani, M | 1 |
| Kuksa, L | 1 |
| Lange, C | 1 |
| Laniado-Laborín, R | 1 |
| Nahid, P | 1 |
| Rodrigues, D | 1 |
| Singla, R | 1 |
| Udwadia, ZF | 1 |
| Menzies, D | 1 |
| Ardhianto, D | 1 |
| Fatmawati, U | 1 |
| Kuaban, C | 1 |
| Noeske, J | 1 |
| Rieder, HL | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 1 |
| Trébucq, A | 1 |
| Xu, HB | 1 |
| Jiang, RH | 1 |
| Xiao, HP | 1 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Biswas, SK | 1 |
| Granstein, RD | 1 |
| Sober, AJ | 1 |
2 reviews available for clofazimine and Adverse Drug Event
| Article | Year |
|---|---|
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Canada; Clofazimine; Diarylquinolines; Drug-Relat | 2020 |
Drug- and heavy metal--induced hyperpigmentation.
Topics: Adrenocorticotropic Hormone; Amiodarone; Antimalarials; Antineoplastic Agents; Argyria; Arsenic; Bis | 1981 |
9 other studies available for clofazimine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Topics: Clofazimine; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Diseases; Nontuberculous | 2022 |
Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug-Related Side Effects and Adverse Reaction | 2021 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Clofazimine in the treatment of multidrug-resistant tuberculosis.
Topics: Adult; Animals; Antitubercular Agents; China; Clofazimine; Drug Resistance, Multiple, Bacterial; Dru | 2012 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 2004 |